TY - JOUR
T1 - Heart failure with preserved ejection fraction in Asia
AU - ASIAN-HF Investigators
AU - Tromp, Jasper
AU - Teng, Tiew-Hwa
AU - Tay, Wan Ting
AU - Hung, Chung Lieh
AU - Narasimhan, Calambur
AU - Shimizu, Wataru
AU - Park, Sang Weon
AU - Liew, Houng Bang
AU - Ngarmukos, Tachapong
AU - Reyes, Eugene B.
AU - Siswanto, Bambang B.
AU - Yu, Cheuk-Man
AU - Zhang, Shu
AU - Yap, Jonathan
AU - MacDonald, Michael
AU - Ling, Lieng Hsi
AU - Leineweber, Kirsten
AU - Richards, A. Mark
AU - Zile, Michael R.
AU - Anand, Inder S.
AU - Lam, Carolyn S. P.
PY - 2019/1
Y1 - 2019/1
N2 - Background: Heart failure with preserved ejection fraction (HFpEF) is a global public health problem. Unfortunately, little is known about HFpEF across Asia.Methods and results: We prospectively studied clinical characteristics, echocardiographic parameters and outcomes in 1204 patients with HFpEF (left ventricular ejection fraction ≥50%) from 11 Asian regions, grouped as Northeast Asia (Hong Kong, Taiwan, China, Japan, Korea, n = 543), South Asia (India, n = 252), and Southeast Asia (Malaysia, Thailand, Singapore, Indonesia, Philippines, n = 409). Mean age was 68 ±12 years (37% were < 65 years) and 50% were women. Seventy per cent of patients had ≥2 co‐morbidities, most commonly hypertension (71%), followed by anaemia (57%), chronic kidney disease (50%), diabetes (45%), coronary artery disease (29%), atrial fibrillation (29%) and obesity (26%). Southeast Asian patients had the highest prevalence of all co‐morbidities except atrial fibrillation, South Asians had the lowest prevalence of all co‐morbidities except anaemia and obesity, and Northeast Asians had more atrial fibrillation. Left ventricular hypertrophy and concentric remodelling were most prominent among Southeast and South Asians, respectively (P < 0.001). Overall, 12.1% of patients died or were hospitalized for heart failure within 1 year. Southeast Asians were at higher risk for adverse outcomes, independent of co‐morbidity burden and cardiac geometry.Conclusion: These first prospective multinational data from Asia show that HFpEF affects relatively young patients with a high burden of co-morbidities. Regional differences in types of co-morbidities, cardiac remodelling and outcomes of HFpEF across Asia have important implications for public health measures and global HFpEF trial design.
AB - Background: Heart failure with preserved ejection fraction (HFpEF) is a global public health problem. Unfortunately, little is known about HFpEF across Asia.Methods and results: We prospectively studied clinical characteristics, echocardiographic parameters and outcomes in 1204 patients with HFpEF (left ventricular ejection fraction ≥50%) from 11 Asian regions, grouped as Northeast Asia (Hong Kong, Taiwan, China, Japan, Korea, n = 543), South Asia (India, n = 252), and Southeast Asia (Malaysia, Thailand, Singapore, Indonesia, Philippines, n = 409). Mean age was 68 ±12 years (37% were < 65 years) and 50% were women. Seventy per cent of patients had ≥2 co‐morbidities, most commonly hypertension (71%), followed by anaemia (57%), chronic kidney disease (50%), diabetes (45%), coronary artery disease (29%), atrial fibrillation (29%) and obesity (26%). Southeast Asian patients had the highest prevalence of all co‐morbidities except atrial fibrillation, South Asians had the lowest prevalence of all co‐morbidities except anaemia and obesity, and Northeast Asians had more atrial fibrillation. Left ventricular hypertrophy and concentric remodelling were most prominent among Southeast and South Asians, respectively (P < 0.001). Overall, 12.1% of patients died or were hospitalized for heart failure within 1 year. Southeast Asians were at higher risk for adverse outcomes, independent of co‐morbidity burden and cardiac geometry.Conclusion: These first prospective multinational data from Asia show that HFpEF affects relatively young patients with a high burden of co-morbidities. Regional differences in types of co-morbidities, cardiac remodelling and outcomes of HFpEF across Asia have important implications for public health measures and global HFpEF trial design.
KW - Heart failure with preserved ejection fraction
KW - Asia
KW - Co-morbidities
KW - Echocardiography
KW - SUDDEN CARDIAC DEATH
KW - CLINICAL CHARACTERISTICS
KW - PATIENT CHARACTERISTICS
KW - EUROPEAN ASSOCIATION
KW - SYSTOLIC FUNCTION
KW - AMERICAN SOCIETY
KW - OUTCOMES
KW - MORTALITY
KW - MANAGEMENT
KW - ECHOCARDIOGRAPHY
U2 - 10.1002/ejhf.1227
DO - 10.1002/ejhf.1227
M3 - Article
SN - 1388-9842
VL - 21
SP - 23
EP - 36
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
IS - 1
ER -